Inhibition of HBsAg secretion by a novel autophagy inducer

abstract in e-form
Creative Commons License IconCreative Commons BY Icon
Thumbnail
File can be accessed.Get publication
Author
Pimková Polidarová, MarkétaORCiD Profile - 0000-0003-3116-1328WoS Profile - V-2351-2017Scopus Profile - 57212310198
Janovec, VáclavORCiD Profile - 0000-0002-6262-3364WoS Profile - N-7608-2017Scopus Profile - 57193086112
Berehovska, Olena
Kůtová, Zuzana
Sedláček, Jindřich
Adámek, Michael
Machara, AlešORCiD Profile - 0000-0002-1139-2762WoS Profile - CDD-3155-2022Scopus Profile - 19337303000
Hirsch, IvanORCiD Profile - 0000-0003-1701-1438WoS Profile - R-3103-2016Scopus Profile - 56275056800
Grantz Šašková, KláraORCiD Profile - 0000-0003-2874-5699WoS Profile - E-1931-2014Scopus Profile - 22954587000
Černý, Jiří
Holá, Lucie
Šímová, Šárka
Dvořáková, Anna
Česká zemědělská univerzita Praha, Česká spol. pro biochemii a mol. bilogii, NIVB

Publication date
2024
Published in
CzechoSlovak Virology Conference 2024 : Book of Abstracts
Publisher / Publication place
Česká zemědělská univerzita v Praze (Praha)
Volume / Issue
1 (1)
Metadata
Show full item record
Collections
Abstract
Chronic hepatitis B (CHB) is a viral liver infection caused by hepatitis B virus (HBV), affecting over 300 million people world-wide. Untreated CHB can lead to liver cirrhosis and hepatocellular carcinoma, causing over 800,000 deaths annually. Current nucleot(s)ide analogue-based therapies effectively slow disease progression and reduce viral load, but require life-long application. Pegylated interferon alpha therapy clears the virus in a small percentage of patients, but has serious side effects. Therefore, a universally effective and definitive cure of CHB is still elusive.
Keywords
inhibitor, HBsAg, HBV
Permanent link
https://hdl.handle.net/20.500.14178/2257
License

Full text of this result is licensed under: Creative Commons Uveďte původ 4.0 International

Show license terms